Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

CNBX Pharmaceuticals (CNBX) Equity Average (2016 - 2025)

CNBX Pharmaceuticals (CNBX) has disclosed Equity Average for 13 consecutive years, with -$2.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average fell 1.5% year-over-year to -$2.5 million, compared with a TTM value of -$2.5 million through Nov 2025, down 1.5%, and an annual FY2025 reading of -$2.5 million, down 10.65% over the prior year.
  • Equity Average was -$2.5 million for Q4 2025 at CNBX Pharmaceuticals, down from -$2.5 million in the prior quarter.
  • Across five years, Equity Average topped out at $3.1 million in Q2 2021 and bottomed at -$2.6 million in Q2 2025.
  • Average Equity Average over 5 years is -$977626.7, with a median of -$2.0 million recorded in 2023.
  • The sharpest move saw Equity Average increased 8.67% in 2021, then crashed 2676.82% in 2023.
  • Year by year, Equity Average stood at $1.3 million in 2021, then plummeted by 113.11% to -$170991.0 in 2022, then crashed by 1102.47% to -$2.1 million in 2023, then decreased by 21.45% to -$2.5 million in 2024, then decreased by 1.5% to -$2.5 million in 2025.
  • Business Quant data shows Equity Average for CNBX at -$2.5 million in Q4 2025, -$2.5 million in Q3 2025, and -$2.6 million in Q2 2025.